Amylin reports earnings

Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) reported 1Q11 revenue of $152.7 million, below the Street's estimate of $156.7 million and down from $174.1 million in 1Q10. First quarter sales of diabetes drug Byetta exenatide fell 15% to $128 million compared to the prior year's period. Amylin and partner Eli Lilly and Co. (NYSE:LLY) market the twice-daily injectable version of exenatide. ...